Ramanand A. Subramanian

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke et al. · The Lancet · 2020 · 322 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis

Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia et al. · Arthritis & Rheumatology · 2020 · 80 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

Christopher T. Ritchlin, Philip Helliwell, Wolf‐­Henning Boehncke et al. · RMD Open · 2021 · 71 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The utility of shock index in differentiating major from minor injury

Lorenzo Paladino, Ramanand A. Subramanian, Spencer G. Nabors et al. · European Journal of Emergency Medicine · 2010 · 49 citations

Medicine, Emergency Medicine, Resuscitation +16

Patients with detectable cocaethylene are more likely to require intensive care unit admission after trauma

Sage E. Wiener, Darrell Sutijono, Cynthia H. Moon et al. · The American Journal of Emergency Medicine · 2010 · 48 citations

Medicine, Emergency Medicine, Trauma Critical Care +1